POG 9572 BYROSTATIN IN CHILDREN WITH SOLID TUMORS

POG 9572 拜罗他汀治疗患有实体瘤的儿童

• 批准号: 6279206
• 负责人: FAITH H KUNG
• 金额: $ 1.43万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279206
• 关键词: antineoplastics; child (0-11); clinical research; clinical trial phase I; cytotoxicity; dosage; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; pharmacokinetics

POG 9572 to determine qualitative and quantitative toxicity of byrostatin administered as one hour iv infusion, establish maximum tolerated dose that results in toelrable toxicity, characterize pharmacokinetics of the drug and observe any anti-tumor effects during escalating doses of drug.

POG 9572确定Byrostatin的定性和定量毒性 以1小时的静脉输注为一小时，建立最大耐受剂量 这导致了可依依的毒性，表征了药代动力学 药物并观察到升级药物期间的任何抗肿瘤作用。